



Title	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
Author(s)	Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.
Citation	Clinical Rheumatology. 2021, 40(7), p. 2673-2680
Version Type	AM
URL	https://hdl.handle.net/11094/93248
rights	© 2021, International League of Associations for Rheumatology (ILAR).
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

Original Article

Title:

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: The ANSWER cohort study

Authors:

Kosuke Ebina^{1*}, Toru Hirano², Yuichi Maeda², Wataru Yamamoto^{3,4}, Motomu Hashimoto⁴, Koichi Murata⁴, Akira Onishi⁵, Sadao Jinno⁵, Ryota Hara⁶, Yonsu Son⁷, Hideki Amuro⁷, Tohru Takeuchi⁸, Ayaka Yoshikawa⁸, Masaki Katayama⁹, Keiichi Yamamoto¹⁰, Makoto Hirao¹¹, Yasutaka Okita², Atsushi Kumanogoh², and Ken Nakata¹²

Affiliations:

1. Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan
2. Department of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan
3. Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan
4. Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5. Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan
6. The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan
7. First Department of Internal Medicine, Kansai Medical University, Osaka, Japan

- 25 8. Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan
- 26 9. Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan
- 27 10. Information Technology Center, Wakayama Medical University Hospital, Wakayama, Japan
- 28 11. Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka,
- 29 Japan
- 30 12. Department of Health and Sport Sciences, Osaka University, Graduate School of Medicine, Osaka,
- 31 Japan

32

33 ***Corresponding author:** E-mail: k-ebina@umin.ac.jp

34

35 **ORCID**

36	Kosuke Ebina	0000-0002-2426-1024
37	Toru Hirano	0000-0001-8467-3154
38	Yuichi Maeda	0000-0002-6831-8205
39	Wataru Yamamoto	0000-0002-0810-4221
40	Motomu Hashimoto	0000-0002-9241-060X
41	Koichi Murata	0000-0002-7896-3937
42	Akira Onishi	0000-0002-3120-1273
43	Sadao Jinno	0000-0003-3021-183X
44	Ryota Hara	0000-0001-8000-3196
45	Tohru Takeuchi	0000-0002-0065-929X
46	Ayaka Yoshikawa	0000-0002-1927-1295
47	Yonsu Son	0000-0001-7244-7715
48	Hideki Amuro	0000-0002-7299-2884
49	Masaki Katayama	0000-0002-0773-7238

50	Makoto Hirao	0000-0002-1408-7851
51	Yasutaka Okita	0000-0003-3620-8412
52	Atsushi Kumanogoh	0000-0003-4749-7117
53	Ken Nakata	0000-0002-8964-4229
54		
55		

56 **Abstract**

57 Objectives: The aim of this multicenter, retrospective study was to clarify the retention rates of
58 sarlumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA).
59 Methods: Patients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females,
60 80.9%; age, 61.0 years; disease duration, 11.1 years; rheumatoid factor positivity, 84.4%; Disease
61 Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone dose,
62 5.3 mg/day [47.0%] and methotrexate dose, 8.8 mg/week [58.4%]; biologics- or Janus kinase
63 inhibitors-switched cases 78.4%) were included. The reasons for drug discontinuation were classified
64 into 4 major categories (lack of effectiveness, toxic adverse events, non-toxic reasons, and remission)
65 by each attending physician. The drug retention rate was estimated at 18 months using the Kaplan–
66 Meier method and adjusted for potential confounders by Cox proportional hazards modeling.
67 Results: The discontinuation rates of SAR, BAR, and TOF for the corresponding reasons were as
68 follows, respectively: lack of effectiveness (15.7%, 15.6%, and 21.5%; P = 0.84), toxic adverse events
69 (15.8%, 12.1%, and 12.3%; P = 0.35), non-toxic reasons (10.9%, 7.7%, and 6.8%; P = 0.35), and
70 remission (0.0%, 2.8%, and 0.0%; P = 1.0). The overall retention rates excluding non-toxic reasons
71 and remission were as follows: 68.8% for SAR, 72.5% for BAR, and 66.7% for TOF (P = 0.54).
72 Conclusions: After adjustment by potent confounders, SAR, BAR, and TOF showed similar
73 discontinuation rates due to lack of effectiveness and toxic adverse events.

74

75 **Keywords**

76 ANSWER cohort, Baricitinib, Drug retention, Rheumatoid arthritis, Sarilumab, and Tofacitinib

77

78 **Key Points**

79 This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for
80 discontinuation of SAR, BAR, and TOF in patients with RA.

81

82 **Abbreviations**

83 Abbreviations are listed in supplementary table 1.

84

Introduction

The recommendations of the 2019 European League Against Rheumatism (EULAR) stated that the efficacies of anti-interleukin (IL)-6 receptor antibody (IL-6R; tocilizumab [TCZ] and sarilumab [SAR]), CTLA4-Ig (abatacept), and Janus kinase inhibitors (JAKi) such as baricitinib (BAR; JAK1 and JAK2 inhibitor) and tofacitinib (TOF; JAK1 and JAK3 inhibitor) are considered equivalent to those of tumor necrosis factor inhibitors (TNFi) in both the phase II and III treatments of rheumatoid arthritis (RA) [1]. The findings of this report also showed no significant differences in outcomes among the biological disease-modifying antirheumatic drugs (bDMARDs) and JAKi, irrespective of their targets. However, cohort-based studies revealed that in patients who showed inadequate response to TNFi, switching to a non-TNFi agent (such as ABT, rituximab, or TCZ) showed significantly higher drug retention rates compared with switching to another TNFi [2,3]. In addition, we recently reported that among bDMARDs-switched patients, those who were taking TCZ and TOF showed lower discontinuation rates due to lack of effectiveness than those who were receiving TNFi, suggesting that anti-IL-6R and JAKi had better retention than TNFi in real-world settings [4].

The use of TOF (2013), SAR (2017), and BAR (2017) was recently approved in Japan, and reliable evidence of direct comparison between these agents is still lacking. SAR is a human IgG1 monoclonal antibody that binds to soluble and membrane-bound IL-6 receptors, and a recent report demonstrated similar safety and laboratory changes between patients treated with SAR and TCZ [5]. JAKi inhibits

the JAK-signal transducer and activator of transcription pathways, which leads to the inhibition of IL-6 and other various cytokines [6]. A recent meta-analysis revealed that in patients with inadequate response (IR) to bDMARDs (bDMARDs-IR), both TOF 10 mg (standard dose in Japan) and BAR 4 mg (standard dose in Japan) with methotrexate (MTX) were efficacious to similar extents [7], although no detailed comparison using data from the same registry has been reported. In a comparison between anti-IL-6R and JAKi in patients with TNFi-IR, TOF showed a lower discontinuation rate due to lack of effectiveness than TCZ [8]. However, we recently reported that in bDMARDs-switched patients, TCZ showed similar good retention due to lack of effectiveness compared to TOF [4]. Taken together, comparison between the effectiveness of anti-IL-6R and JAKi still remains unclear. Moreover, SAR, BAR, and TOF tended to be introduced in patient with multiple bDMARDs failure or intolerance to MTX due to comorbidities in real-world settings, which is quite different from those recruited in randomized controlled trials. Therefore, investigating the effectiveness and safety of these agents in “difficult-to-treat” RA patients are of great interest. Recently, cohort-based observational studies have increasingly been conducted to investigate the performance of bDMARDs [9,10]. In these studies, drug retention is considered a major index of both treatment safety and effectiveness [11,12]. On the basis of our findings from our cohort, we have recently reported the drug retention rates of bDMARDs [4,13,14,15] (summaries of these studies are listed in supplementary table 2) and factors associated with the achievement of bDMARDs-free

remission [16]. The aim of the present multicenter retrospective study was to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in real-world settings.

Materials and Methods

Patients

The Kansai Consortium for Well-being of Rheumatic Disease Patients (ANSWER) cohort is an observational multicenter registry of patients with RA in the Kansai district of Japan. Data were retrospectively collected from patients who were examined at 7 major university-related hospitals (Kyoto University, Osaka University, Osaka Medical College, Kansai Medical University, Kobe University, Nara Medical University, and Osaka Red Cross Hospital). RA was diagnosed on the basis of either the 1987 RA classification criteria of the American College of Rheumatology (ACR) [17] or the 2010 ACR/EULAR RA classification criteria [18].

Patients who were treated by senior rheumatologists with either SAR, BAR, or TOF between 2013 and 2020 with complete data on the start and discontinuation dates and the reasons for discontinuation were included in this study. In addition, their baseline demographic data such as age; sex; disease duration; disease activity (Disease Activity Score in 28 joints using erythrocyte sedimentation rate [DAS28-ESR]); Clinical Disease Activity Index score; concomitant doses (calculated as a blank when not combined) and ratios of methotrexate (MTX) and prednisolone (PSL); concomitant ratio of other

conventional disease-modifying antirheumatic drugs (csDMARDs) such as salazosulfapyridine (SASP), bucillamine, iguratimod, tacrolimus, and leflunomide; rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody positivity; and Health Assessment Questionnaire Disability Index score were also collected [4,13,14,19].

In Japan, the national health insurance covers 70%–90% of the medical expense, and bDMARDs or JAKi can be administered at the discretion of attending rheumatologists in accordance with the Japan College of Rheumatology guidelines (generally in patients who showed inadequate response to csDMARDs or with high risk of progressive joint destruction) [20,21,22]. The dose of each agent is determined in accordance with the manufacturer's recommendation. Drug retention was retrospectively evaluated as the duration until definitive treatment interruption. The reasons for discontinuation were analyzed and classified into four major categories as follows: 1) lack of effectiveness (including primary and secondary); 2) toxic adverse events (infection, skin or systemic reaction, and other toxic events, including hematologic, pulmonary, renal, cardiovascular complications, and malignancies); 3) non-toxic reasons (patient preference, change in hospital, desire for pregnancy, etc.); and 4) disease remission [4,13,14,15,19]. Physicians were allowed to cite only one reason for discontinuation.

Statistical analyses

The differences in baseline clinical characteristics between the groups were assessed using an analysis of variance for continuous variables and the Fisher exact test for categorical variables. The Kaplan–Meier method was used to examine the survival curves for the agents as determined by the specific causes. The hazard ratio (HR) for treatment discontinuation at 18 months was analyzed and statistically compared using multivariate Cox proportional hazards modeling [9,13,14,19]. The analysis was adjusted for the potential confounders that could influence drug retention as previously described (age; sex; disease duration; concomitant PSL, MTX, and SASP use; and number of switched bDMARDs or JAKi) [9,13,14,15,19]. Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for the R software (The R Foundation for Statistical Computing, Vienna, Austria) [23]. A P value < 0.05 was considered statistically significant.

Results

Table 1 presents the baseline clinical characteristics of the patients at treatment initiation with each agent (female, 80.9%; age, 61.0 years; disease duration, 11.1 years; RF positivity, 84.4%; DAS28-ESR, 4.3; concomitant PSL dose, 5.3 mg/day and ratio, 47.0%; MTX dose, 8.8 mg/week and ratio, 58.4%; and bDMARDs or JAKi switched cases, 78.4%). Overall, patients were treated by high dose and ratio of PSL, low dose and ratio of MTX, and mostly switched from other bDMARDs or

JAKi, suggesting “difficult-to-treat” backgrounds. We found significant differences in sex ratio ($P = 0.02$), disease duration ($P = 0.02$), MTX use ($P = 0.03$), SASP use ($P = 0.01$), and prior use of JAKi ($P < 0.001$) between the groups. SAR (25.8%) and BAR (20.5%) showed higher rate of prior use of JAKi compared to TOF (6.5%).

The adjusted drug discontinuation rates of SAR, BAR, and TOF for the corresponding reasons were as follows, respectively: lack of effectiveness (15.7%, 15.6%, and 21.5%; $P = 0.84$ between the groups; Fig. 1a), toxic adverse events (15.8%, 12.1%, and 12.3%; $P = 0.35$ between the groups; Fig. 1b), non-toxic reasons (10.9%, 7.7%, and 6.8%; $P = 0.35$ between the groups; Fig. 2a), and remission (0.0%, 2.8%, and 0.0%; $P = 1.0$ between the groups). The overall retention rates excluding non-toxic reasons and remission were as follows: 68.8% for SAR, 72.5% for BAR, and 66.7% for TOF ($P = 0.54$ between the groups; Fig. 2b).

Table 2 shows the adjusted HRs for the reasons of discontinuation. The HR due to lack of effectiveness was similar between the groups ($P = 0.84$). The HR due to toxic adverse events tended to be lower for BAR (0.58) and TOF (0.57) than for SAR. The HR due to non-toxic events also tended to be lower for BAR (0.58) and TOF (0.50) than for SAR, although no significant difference was observed ($P = 0.35$ between the groups). Finally, we found no significant difference in the HR for total discontinuation (excluding non-toxic reasons and remission) between the groups ($P = 0.54$).

Discussion

To the best of our knowledge, this is the first study to directly compare the reasons of discontinuation and retention rates of SAR, BAR, and TOF in the same multicenter cohort. Concerning the differences of SAR and TCZ, a previous report demonstrated that SAR showed higher affinities to recombinant human and monkey IL-6R with a 10- to 40-fold greater dissociation constant (K_d) value than TCZ in vitro [24]. However, a recent report demonstrated no clinically meaningful differences in both safety and laboratory changes between the patients treated with SAR and TCZ [5]. In addition, switching intravenous TCZ to SAR sustained both clinical efficacy and safety [25]. Taken together, as far as we know, SAR may exhibit similar clinical effectiveness and safety as TCZ.

Concerning JAKi, only a few meta-analyses have compared the effectiveness and safety of BAR and TOF. Recent reports demonstrated that in patients with MTX-IR [26] or bDMARDs-IR [27], BAR 4 mg (standard dose in Japan) with MTX showed a higher American College of Rheumatology 20% (ACR20) or ACR50 response rate than TOF 5 mg (10mg is standard dose in Japan) with MTX.

However, another meta-analysis revealed that in patients with csDMARDs-IR or bDMARDs-IR, BAR 4 mg and TOF 10 mg with MTX were both efficacious to similar extents [7]. Taken together, TOF 5 mg may be inferior, although TOF 10 mg may be equivalent to BAR 4 mg, which is in accordance with the results of the present study.

210 In a comparison of anti-IL-6R and JAKi in patients with TNFi-IR, TOF showed a lower
211 discontinuation rate due to lack of effectiveness than TCZ [8]. However, we recently reported that in
212 bDMARDs-switched patients, TOF and TCZ showed similar better retention due to lack of
213 effectiveness compared to TNFi [4]. Comparing SAR and TOF, a systematic review and network
214 meta-analysis demonstrated that in patients with csDMARDs-IR, SAR 200 mg (standard dose in
215 Japan) monotherapy showed a similar effectiveness and safety compared to TOF [28]. On the other
216 hand, another systematic review showed that in csDMARDs-IR and TNFi-IR patients, SAR 200 mg
217 with csDMARDs showed superiority to BAR 2 mg in terms of ACR50 and DAS28<2.6 achievement,
218 and to BAR 2 mg and TOF (dose not mentioned) in terms of the 24-week modified total Sharp score
219 progression [29]. In addition, SAR 150 mg showed superiority to BAR 2 mg, and similarity to other
220 JAKi in terms of DAS28<2.6 achievement [29]. Taken together, SAR may exhibit at least similar
221 effectiveness and safety to BAR and TOF, which is in accordance with the results of our present study.
222 Considering the underlying mechanisms, a recent report demonstrated that IL-6 is one of the most
223 dominant cytokines in both seropositive and seronegative RA patients [30]. In addition, anti-IL-6R
224 therapy is associated with relatively low incidence of antidrug antibody production regardless of
225 csDMARDs combination, as IL-6 itself promotes antibody production [31]. BAR inhibits JAK1 and
226 JAK2, and TOF inhibits JAK1 and JAK3 signaling, which are both involved in IL-6 production [6].

227 Although difficult to compare the degree, substantial inhibition of IL-6 by SAR, BAR, and TOF may
228 lead to similar clinical effectiveness and safety in a certain patients' population.

229 The effectiveness of low-dose MTX in Japanese populations should be considered. Intra-erythrocyte
230 MTX-polyglutamate (MTX-PG) concentration, which is considered a useful biomarker of MTX
231 efficacy, was 65 nmol/L with 13.4-mg/week dose of MTX in the United States patients, although
232 reached 94 nmol/L with 10.3-mg/week dose of MTX in Japanese patients [32]. Thus, a relatively low
233 MTX dose may exhibit positive effects in Japanese populations.

234 The limitations of the present study were as follows: First, the number of patients in the study was
235 small (especially that of patients who received SAR), and in spite of the adjustment, the difference of
236 patients' background (including combined medications such as MTX and SASP, and prior
237 medications of bDMARDs and JAKi) between the groups may have affected the results. Second, the
238 judgment and reasons for discontinuation (e.g., lack of effectiveness or remission) depended on the
239 decisions of each physician, without standardized criteria. Third, as the initial dose of each agent was
240 determined according to the manufacturer's recommendations, minor dose changes of each agent
241 during the period could not be monitored. Fourth, comorbidities, which can potentially affect drug
242 retention, could not be evaluated. Fifth, the data is limited to Japanese and may differ from that of
243 western populations, and future studies with longer follow-up may be required. However, the strength

244 of this study is that as far as we know, this is the first study to directly compare the drug retention rates
245 and reasons for discontinuation of SAR, BAR, and TOF in the same multicenter cohort.
246 After adjustment for the potent confounders, SAR, BAR, and TOF showed similar discontinuation
247 rates due to lack of effectiveness and toxic adverse events, and total drug retention rates. These
248 findings may provide new insight into the decision to use these agents in clinical practice.
249

250 **Acknowledgments**

251 We thank all the medical staff at all the institutions who participated in the ANSWER cohort for
252 providing the data.

253

254 **Declarations**

255 **Funding**

256 The study reported in this publication uses the ANSWER Cohort, was supported by grants from 10
257 pharmaceutical companies (AbbVie GK, Asahi-Kasei, Ayumi, Chugai, Eisai, Janssen K.K, Ono,
258 Sanofi K.K, Teijin Healthcare, and UCB Japan) and an information technology service company
259 (CAC). This study was conducted as an investigator-initiated study. These companies had no roles in
260 the study design, data collection, data analysis, data interpretation, or writing of the report.

261

262 **Conflict of interest**

263 KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University,
264 Graduate School of Medicine, which is supported by Taisho. KE has received research grants from
265 Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Ono Pharmaceutical, Teijin Pharma,
266 and UCB Japan. KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi,
267 Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical,

268 Pfizer, Sanofi, and UCB Japan. TH received a research grant and/or speaker fee from Astellas, Chugai,
269 GlaxoSmithKline, Nippon Shinyaku, and Eisai. YM received a research grant and/or speaker fee from
270 Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe. MHashimoto and KM are
271 affiliated with a department that is financially supported by four pharmaceutical companies
272 (Asahi-Kasei, Mitsubishi-Tanabe, Chugai, Ayumi, and UCB Japan) and the city government
273 (Nagahama City). MHashimoto received a research grant and/or speaker fee from Mitsubishi-Tanabe,
274 Eisai, Eli Lilly, and Bristol-Myers Squibb. KM received a speaker fee from Eisai. TT is affiliated with
275 a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe,
276 Chugai, Ayumi, Astellas, Eisai, and Takeda). TT received a research grant from Chugai, cover letter
277 and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, AbbVie, Bristol-Myers Squibb,
278 Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei. AO received a speaker fee from Chugai, Ono
279 Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda. SJ has received speaking fees
280 from AbbVie, Asahi-Kasei, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen Pharmaceutical,
281 Mitsubishi-Tanabe, and Ono Pharmaceutical. RH received a speaker fee from AbbVie. MHirao
282 received a speaker fee from Astellas, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Ayumi,
283 and Takeda. AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai,
284 Asahi-Kasei, Astellas, AbbVie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer. KN has
285 received a research grant from Astellas, and supervises the Department of Musculoskeletal

Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. WY, YS, HA, AY, MK, KY, and YO have no financial conflicts of interest to disclose concerning this manuscript. These companies had no role in the study design, data collection, data analysis, data interpretation, and preparation of the manuscript.

Ethical approval

The representative facility of this registry was Kyoto University, and this observational study was conducted in accordance with the Declaration of Helsinki, with the approval of the ethics committees of the following seven institutes: Kyoto University (2016-03-24/approval No. R053), Osaka University (2015-11-04/approval No. 15300), Osaka Medical College (2014-07-14/approval No. 1529), Kansai Medical University (2017-11-21/approval No. 2014625), Kobe University (2015-03-20/approval No. 1738), Nara Medial University (2018-01-23/approval No. 1692), and Osaka Red Cross Hospital (2015-09-01/approval No. 644). The board of the Osaka University Hospital Ethics Committee waived the requirement for patient informed consent because of the anonymous nature of the data. Written informed consent was obtained from the participants in other institutes.

Consent for participation and publication

The board waived the requirement for patient informed consent by posting the opt-out information in

the hospitals' home page.

Availability of data and materials

The datasets used and/or analyzed in the present study are available from the corresponding author on reasonable request.

Authors' contributions

KE was responsible for conception and design. KE, TH, YM, YO, MH, KM, AO, SJ, RH, TT, AY, YS, HA, and MK contributed to data extraction and interpretation. KE, WY, and KY contributed to the design and conduction of statistical analysis. KE and MH prepared the manuscript. AK, MH, and KN supervised the manuscript. All the authors read and approved the final manuscript.

References

1. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruysen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 79: 685-699.
2. Du Pan SM, Scherer A, Gabay C, Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. *Ann Rheum Dis* 71: 997-999.
3. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. *Rheumatology (Oxford)* 53: 1664-1668.
4. Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M (2020) Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. *Arthritis Res Ther* 22: 142.
5. Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A (2019) Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 58: 849-858.
6. Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. *Nat Rev Rheumatol* 13: 234-243.
7. Bae SC, Lee YH (2019) Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. *Z Rheumatol* 78: 559-567.
8. Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV (2016) Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. *Clin Ther* 38: 2628-2641 e2625.
9. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum* 61: 560-568.
10. Favalli EG, Pregnotato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL (2016)

- Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. *Arthritis Care Res (Hoboken)* 68: 432-439.
11. Hyrich KL, Watson KD, Lunt M, Symmons DP (2011) Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. *Rheumatology (Oxford)* 50: 117-123.
 12. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. *Ann Rheum Dis* 74: 354-360.
 13. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. *PLoS One* 14: e0216624.
 14. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. *Arthritis Res Ther* 21: 91.
 15. Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Nagai K, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M (2020) Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. *Clin Rheumatol* 39: 2563-2572.
 16. Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. *Arthritis Res Ther* 20: 165.
 17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 31: 315-324.
 18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 69: 1580-1588.
 19. Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A,

- Yoshikawa H (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. *PLoS One* 13: e0194130.
20. Kawahito Y (2016) [Guidelines for the management of rheumatoid arthritis]. *Nihon Rinsho* 74: 939-943.
21. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod Rheumatol* 19: 351-357.
22. Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. *Mod Rheumatol* 17: 451-458.
23. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 48: 452-458.
24. Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. *Arch Pharm Res* 38: 575-584.
25. Emery P, van Hoogstraten H, Thangavelu K, Mangan E, St John G, Verschueren P (2020) Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. *ACR Open Rheumatol* 2: 672-680.
26. Lee YH, Song GG (2020) Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. *Z Rheumatol* 79: 785-796.
27. Lee YH, Song GG (2020) Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. *Z Rheumatol*.
28. Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM (2019) Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs. *Adv Ther* 36: 817-827.
29. Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM (2019) Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor alpha inhibitors: systematic literature review and network meta-analyses. *RMD Open* 5: e000798.
30. Ridgley LA, Anderson AE, Pratt AG (2018) What are the dominant cytokines in early rheumatoid arthritis? *Curr Opin Rheumatol* 30: 207-214.
31. Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC (2017) Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. *Ann Rheum Dis* 76: 1078-1085.
32. Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, Takeuchi T (2017)

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3: e000363.

Figure Legends

Figure 1. Adjusted drug retention due to lack of effectiveness (a) and toxic adverse events (b).

Adjusted confounders included age, sex, disease duration, concomitant prednisolone, methotrexate, and salazosulfapyridine, and number of switched biologics bDMARDs or JAKi.

TOF = Tofacitinib, BAR = Baricitinib, SAR = Sarilumab, bDMARDs = biological disease-modifying antirheumatic drugs, JAKi = Janus kinase inhibitors.

Figure 2. Adjusted drug retention due to non-toxic reasons (a) and total drug retention excluding non-toxic reasons and remission (b).

Adjusted confounders included age, sex, disease duration, concomitant prednisolone, methotrexate, and salazosulfapyridine, and number of switched biologics bDMARDs or JAKi.

TOF = Tofacitinib, BAR = Baricitinib, SAR = Sarilumab, bDMARDs = biological disease-modifying antirheumatic drugs, JAKi = Janus kinase inhibitors.

Table 1. Patients' clinical characteristics at treatment initiation with each agent

Variable	SAR (n = 62)	BAR (n = 166)	TOF (n = 185)	P value
Age (years)	63.8 ± 11.8	60.2 ± 13.5	60.7 ± 13.1	0.17
Female sex (%)	82.3	86.7	75.1	0.02
Disease duration (years)	11.4 ± 10.7	12.6 ± 10.6	9.7 ± 8.3	0.02
RF positivity (%)	86.8	86.1	81.6	0.64
ACPA positivity (%)	75.0	82.0	83.1	0.44
DAS28-ESR	4.1 ± 1.4	4.3 ± 1.3	4.3 ± 1.3	0.50
CDAI	15.6 ± 8.7	17.2 ± 11.0	18.8 ± 11.1	0.18
HAQ-DI	1.1 ± 0.8	0.9 ± 0.7	0.9 ± 0.8	0.62
PSL use (%)	48.4	42.8	50.3	0.36
PSL dose (mg/day)	5.2 ± 3.0	4.7 ± 3.2	5.7 ± 3.3	0.11
MTX use (%)	45.2	64.5	57.3	0.03
MTX dose (mg/week)	7.9 ± 4.1	8.7 ± 3.1	9.2 ± 3.3	0.15
SASP use (%)	16.1	11.4	23.8	0.01
BUC use (%)	9.7	7.8	8.6	0.86
IGU use (%)	24.2	13.3	17.8	0.13
TAC use (%)	14.5	15.7	9.7	0.21
LEF use (%)	0.0	0.0	0.0	N.A.
bDMARDs or JAKi naïve (%)	11.3	22.3	24.3	0.08
2nd bDMARDs or JAKi (%)	25.8	23.5	24.3	0.93
≥3rd bDMARDs or JAKi (%)	62.9	54.2	51.4	0.29
Prior TNFi use (%)	64.5	57.8	65.9	0.28
Prior anti-IL-6R use (%)	51.6	36.1	40.5	0.11
Prior CTLA4-Ig (abatacept) use (%)	32.3	31.9	25.4	0.34
Prior JAKi use (%)	25.8	20.5	6.5	< 0.001

Values are presented as mean ± standard deviation or percentage.

N.A., not applicable; SAR, sarilumab; BAR, baricitinib; TOF, tofacitinib; RF, rheumatoid factor; ACPA, anticyclic citrullinated peptide antibody; DAS28-ESR, Disease Activity Score in 28 joints using erythrocyte sedimentation rate; CDAI, clinical disease activity index; HAQ-DI, Health Assessment Questionnaire disability

6 index; PSL, prednisolone; MTX, methotrexate; SASP, salazosulfapyridine; BUC, bucillamine; IGU, iguratimod;
7 TAC, tacrolimus; LEF, leflunomide; bDMARDs, biological disease-modifying antirheumatic drugs; JAKi, Janus
8 kinase inhibitor: TNFi, tumor necrosis factor inhibitors; IL-6R, interleukin-6 receptor; CTLA4-Ig, cytotoxic T
9 lymphocyte-associated antigen-4-Ig.
10 Differences between the groups were assessed using an analysis of variance or the Fisher exact test.
11

Table 2. Hazard ratios for treatment discontinuation in the cases (Cox proportional hazards model: adjusted for baseline age; sex; disease duration; concomitant PSL, SASP, and MTX use; and number of bDMARDs- or JAKi-switched cases)


	Reference	HR (95% CI)		P value
Variable	SAR (n = 62)	BAR (n = 166)	TOF (n = 185)	
Lack of effectiveness	1	0.87 (0.40–1.90)	1.02 (0.49–2.15)	0.84
Toxic adverse events	1	0.58 (0.25–1.32)	0.57 (0.26–1.29)	0.35
Non-toxic events	1	0.58 (0.22–1.53)	0.50 (0.20–1.29)	0.35
Total discontinuation (excluding non-toxic reasons and remission)	1	0.73 (0.41–1.28)	0.81 (0.47–1.38)	0.54

PSL, prednisolone; SASP, salazosulfapyridine; MTX, methotrexate; bDMARDs, biological disease-modifying antirheumatic drugs; JAKi, Janus kinase inhibitors; HR, hazard ratio; 95% CI, 95% confidence interval; SAR, sarilumab; BAR, baricitinib; TOF, tofacitinib.

Differences between the groups were assessed using the Cox P value.

Figure 1


a Drug retention due to lack of effectiveness



Number at risk

BAR	166	116	72	42
SAR	62	40	25	9
TOF	185	142	127	105

b Drug retention due to toxic adverse events




Number at risk

BAR	166	116	72	42
SAR	62	40	25	9
TOF	185	142	127	105

Figure2


a Drug retention due to non-toxic reasons



Number at risk

BAR	166	116	72	42
SAR	62	40	25	9
TOF	185	142	127	105

b Total retention excluding non-toxic reasons and remission



Number at risk

BAR	166	116	72	42
SAR	62	40	25	9
TOF	185	142	127	105

1	Supplementary table 1. List of abbreviations
2	
3	ACPA; anticyclic citrullinated peptide antibody
4	ANSWER; The Kansai Consortium for Well-being of Rheumatic Disease Patients
5	BAR; baricitinib
6	bDMARDs; biological disease-modifying antirheumatic drugs
7	BUC; bucillamine
8	CDAI; clinical disease activity index
9	csDMARDs; conventional disease-modifying antirheumatic drugs
10	CTLA4-Ig; cytotoxic T lymphocyte-associated antigen-4-Ig
11	DAS28-ESR; Disease Activity Score in 28 joints using erythrocyte sedimentation rate
12	HAQ-DI; Health Assessment Questionnaire disability index
13	HR; hazard ratio
14	IGU; iguratimod
15	IL-6R; interleukin-6 receptor
16	IR; inadequate response
17	JAKi; Janus kinase inhibitor
18	LEF; leflunomide
19	MTX; methotrexate
20	PSL; prednisolone
21	RA; rheumatoid arthritis
22	RF; rheumatoid factor
23	SAR; sarilumab
24	SASP; salazosulfapyridine
25	TAC; tacrolimus
26	TCZ; tocilizumab
27	TNFi; tumor necrosis factor inhibitors
28	TOF; tofacitinib
29	

Supplementary table 2. Summary of drug retention in ANSWER cohort

Ebina K et al. PLOSONE 2018 [1]

- 1,037 treatment courses of 750 RA patients.
- Treatment courses included abatacept (ABT; n = 221), adalimumab (ADA; n = 115), certolizumab pegol (CZP; n = 82), etanercept (ETN; n = 141), golimumab (GLM; n = 175), infliximab (IFX; n = 88), and tocilizumab (TCZ; n = 215).
- Drug retention at 36 months were estimated using the Kaplan-Meier method and adjusted by potent confounders using Cox proportional hazards modeling.
- ABT and TCZ showed higher overall retention, and TCZ showed lower inefficacy compared to IFX, while IFX showed higher discontinuation due to remission compared to ABT, ETN, GLM, and TCZ in adjusted modeling.

Ebina K et al. PLOSONE 2019 [2]

- 1,098 treatment courses of 661 elderly RA patients (65 years of age or older).
- Treatment courses included abatacept (ABT; n = 272), tocilizumab (TCZ; n = 234), etanercept (ETN; n = 184), golimumab (GLM; n = 159), infliximab (IFX; n = 101), adalimumab (ADA; n = 97), and certolizumab pegol (CZP; n = 51).
- Drug retention rates were estimated at 36 months using the Kaplan-Meier method and adjusted for potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX, starting date and switched number of bDMARDs).
- Drug retention rates for each discontinuation reason were as follows; lack of effectiveness [from 55.4% (ETN) to 81.6% (ABT); with significant differences between groups (Cox $P < 0.001$)], toxic adverse events [from 79.3% (IFX) to 95.4% (ABT), Cox $P = 0.043$], and remission [from 94.2% (TCZ) to 100.0% (CZP), Cox $P = 0.58$]. Finally, overall retention rates excluding non-toxic reasons and remission for discontinuation ranged from 50.0% (ETN) to 78.1% (ABT) (Cox $P < 0.001$).

Ebina K et al. Arthritis Research & Therapy 2019 [3]

- 4,466 treatment courses of 2,494 RA patients.
- Treatment courses included tocilizumab (TCZ; n = 895), etanercept (ETN; n = 891), infliximab (IFX; n = 748), abatacept (ABT; n = 681), adalimumab (ADA; n = 558), golimumab (GLM; n = 464), and certolizumab pegol (CZP; n = 229).
- Drug retention rates were estimated at 36 months using the Kaplan-Meier method and adjusted for potential confounders (age, sex, disease duration, concomitant PSL and MTX, and switched number of bDMARDs) using Cox proportional hazards modeling.

- Drug retention rates for each discontinuation reason were as follows: lack of effectiveness [from 65.5% (IFX) to 81.7% (TCZ); with significant differences between groups (Cox P < 0.001)], toxic adverse events [from 81.8% (IFX) to 94.0% (ABT), Cox P < 0.001], and remission [from 92.4% (ADA and IFX) to 97.7% (ETN), Cox P < 0.001]. Finally, overall retention rates excluding non-toxic reasons and remission for discontinuation ranged from 53.4% (IFX) to 75.5% (ABT) (Cox P < 0.001).

Ebina K et al. Arthritis Research & Therapy 2020 [4]

- 4,415 treatment courses of 3,897 RA patients (2,737 bDMARDs-naïve courses and 1,678 bDMARDs-switched courses).
- Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and tofacitinib (TOF; n = 101).
- Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray's test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model.
- Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents).

Abbreviations

bDMARDs = biological disease-modifying antirheumatic drugs, ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, TOF = tofacitinib, PSL = prednisolone, MTX = methotrexate.

References

1. Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, et al. Drug retention and

- discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. 2018; 13(3): e0194130.
2. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. 2019; 14(5): e0216624.
3. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. 2019; 21(1): 91.
4. Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2020; 22(1): 142.